Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31610776 | 0.91 | LPAR1 (0.59) | LPAR1CYP3A4 | |
| SCHEMBL30168359 | 0.90 | LPAR1 (0.62) | LPAR1CYP3A4 | |
| SCHEMBL25001812 | 0.90 | LPAR1 (0.58) | LPAR1CYP3A4 | |
| SCHEMBL25000981 | 0.89 | LPAR1 (0.59) | LPAR1CYP3A4 | |
| SCHEMBL25000926 | 0.89 | LPAR1 (0.60) | LPAR1CYP3A4 | |
| SCHEMBL25000938 | 0.88 | LPAR1 (0.64) | LPAR1CYP3A4 | |
| SCHEMBL30168386 | 0.88 | LPAR1 (0.64) | LPAR1CYP3A4 | |
| SCHEMBL31610907 | 0.88 | LPAR1 (0.58) | LPAR1CYP3A4 | |
| SCHEMBL25001162 | 0.88 | LPAR1 (0.59) | LPAR1CYP3A4 | |
| SCHEMBL25000993 | 0.88 | LPAR1 (0.59) | LPAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179045-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | CONTINEUM THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2023014907-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179045-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR3 | LPAR1 1/4885CYP3A4 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.